Management Team (you are here)
Board Members
Medical Advisory Board
Peter Johann Ph.D. CEO of Lumendi Ltd. UK
Dr. Peter Johann is a Managing General Partner of NGN Capital since 2004 and invested successfully in biotech and medical device companies.
Prior to joining NGN he was the Division Head of Corporate Development at Boehringer Ingelheim. His responsibilities included strategic planning, strategic projects, M&A, business development and licensing. He identified and evaluated licensing, M&A and co-promotion deals.
Prior to this Dr. Johann held several positions in marketing, business development, sales and product management at F. Hoffmann-La Roche, Boehringer Mannheim, Kaneka and Röhm.
Mike Parrilla, COO Lumendi LLC
Mike Parrilla is the Chief Operating Officer of Lumendi LLC.
He is a Senior Operations executive with over (35) years of progressive experience managing Medical Device and high technology companies, products and personnel.
Mr Parrilla is responsible for strategy and execution as far as Lumendi’s US market is concerned. He is also spearheading the work with the FDA (U.S. Food and Drug Administration).
Most recently he held the position of Senior Vice President, Corporate Manufacturing Operations for Hologic, Inc. Hologic is a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products.
The company’s core business units focus on breast cancer detection and intervention, osteoporosis assessment, GYN Surgical and molecular diagnostic assays, instrumentation and disposable products.
See our blog entry about our COO Mike Parrilla
William Wick, Chief Financial Officer
Mr. Wick has gained significant experience in such areas as finance, strategic planning, corporate infrastructure, operations, grants and contracts.
Besides he has been responsible for HR, financial planning and reporting, as well as taxation as Chief Financial Officer and Chief Operating Officer of Vivaldi Biosciences and as CFO of Vision Capital a trans-Atlantic venture capital firm.
My name is udo haas phd; I was working my active live with the Roche company, now retired . I am interested in your company and consider to probably invest in your company. Can you provide me with adequate financial information?
Thank you and best regards
Udo Haas
Dear Mr Haas
Thanks so much for leaving a reply here. I will send you an e-mail and will make sure that you can get the information you need.
As you know, this company is still in the early stages so there is still a lot of work to do. But on December 6 we received the 510(k) clearance from the FDA in the USA.
Auf Deutsch gibt es den Beitrag hier ), so we have come a long way in a short time.
Thanks again for sharing.
Happy Holidays
Urs